{"id":26652,"date":"2024-04-19T10:55:35","date_gmt":"2024-04-19T08:55:35","guid":{"rendered":"https:\/\/www.unither-pharma.biz\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/"},"modified":"2026-04-15T15:33:00","modified_gmt":"2026-04-15T13:33:00","slug":"time2chat-suivi-medical-des-patients-atteints-dun-glaucome","status":"publish","type":"post","link":"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/","title":{"rendered":"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome"},"content":{"rendered":"

Communiqu\u00e9 de presse \u2013 25 avril 2024<\/p>\n

CP Curecall – avril 2024<\/a><\/p>\n

 <\/p>\n

Curecall, Bouygues Telecom et CM.com r\u00e9volutionnent le suivi m\u00e9dical des patients atteints d\u2019un glaucome gr\u00e2ce \u00e0 la solution Time2Chat<\/h2>\n

 <\/p>\n

Curecall, pionnier du suivi m\u00e9dical \u00e0 distance des patients chroniques, CM.com et Bouygues Telecom s’associent pour mettre en place le suivi \u00e0 distance des patients atteints d\u2019un glaucome et pr\u00e9sentent un Proof of Concept (POC) utilisant pour la 1\u00e8re fois en France Time2Chat, solution de SMS conversationnel.<\/p>\n

 <\/p>\n

V\u00e9ritable r\u00e9volution dans l’univers du conversationnel, Time2Chat permet \u00e0 chaque \u00e9tablissement de sant\u00e9 de disposer d\u2019un canal de communication sp\u00e9cifique pour converser directement par SMS avec ses patients gr\u00e2ce \u00e0 un num\u00e9ro sp\u00e9cifique en 093X.<\/p>\n

 <\/p>\n

Maladie oculaire chronique touchant des millions de personnes dans le monde, le glaucome n\u00e9cessite un suivi m\u00e9dical r\u00e9gulier et personnalis\u00e9 pour pr\u00e9venir la perte de vision. Time2Chat, solution universelle et gratuite pour le patient, est un moyen de fluidifier les \u00e9changes avec l\u2019\u00e9quipe m\u00e9dicale. Simple et efficace, elle garantit un suivi r\u00e9gulier, adapt\u00e9 \u00e0 leurs besoins.<\/p>\n

 <\/p>\n

En combinant l’expertise de Bouygues Telecom en mati\u00e8re de communication mobile et la solution de suivi patient de Curecall, ce partenariat novateur vise \u00e0 r\u00e9volutionner la prise en charge du glaucome et \u00e0 am\u00e9liorer la qualit\u00e9 de vie des patients. <\/strong><\/p>\n

 <\/p>\n

\u00ab\u00a0Nous sommes fiers de collaborer avec Bouygues Telecom pour d\u00e9velopper le POC Time2Chat et offrir aux patients atteints de glaucome un suivi m\u00e9dical \u00e0 distance de qualit\u00e9\u00a0\u00bb, d\u00e9clare Mohammed El Bojaddaini, CEO de Curecall<\/strong><\/p>\n

 <\/p>\n

\u00ab\u00a0Ce partenariat illustre notre engagement commun \u00e0 innover dans le domaine de la sant\u00e9 connect\u00e9e et \u00e0 fournir des solutions technologiques qui r\u00e9pondent aux besoins des patients et des professionnels de sant\u00e9.\u00a0\u00bb<\/p>\n

 <\/p>\n

\u00ab\u00a0Chez Bouygues Telecom, nous sommes ravis de voir \u00e9merger les premi\u00e8res applications de la solution innovanteTime2Chat pour am\u00e9liorer les soins de sant\u00e9 et faciliter le suivi m\u00e9dical \u00e0 distance\u00a0\u00bb, d\u00e9clare Renan Abgrall, directeur de la Value Factory. <\/strong><\/p>\n

 <\/p>\n

\u00ab\u00a0Le programme partenaire CM.com en France est une grande force pour nous. En int\u00e9grant nos APIs sur des plateformes tierces, nous permettons \u00e0 nos partenaires de se concentrer sur leur coeur de m\u00e9tier. Avec Curecall et Bouygues Telecom, CM.com franchit une \u00e9tape suppl\u00e9mentaire en accompagnant les experts de la d\u00e9mat\u00e9rialisation du suivi patient, une premi\u00e8re mondiale sur ce canal et dans l’exp\u00e9rience patient propos\u00e9e. \u00bb Pierre Garrigues, Directeur France de CM.com<\/strong><\/p>\n

 <\/p>\n

\u00c0 propos de Curecall :<\/strong><\/h3>\n

Curecall est une entreprise sp\u00e9cialis\u00e9e dans le suivi m\u00e9dical \u00e0 distance des patients
\nchroniques, offrant des solutions innovantes pour am\u00e9liorer la prise en charge des maladies
\nchroniques et favoriser l’autonomie des patients.
\ncurecall.fr<\/a><\/p>\n

 <\/p>\n

\u00c0 propos de CM.com :<\/strong><\/h3>\n

CM.com (CMCOM.AS) est une plateforme omnicanale permettant sur l\u2019ensemble des canaux
\nde communication de faire le lien entre les entreprises et leurs patients. En offrant des
\nexp\u00e9riences uniques, personnalis\u00e9es et automatis\u00e9es.<\/p>\n

CM.com<\/a><\/p>\n

 <\/p>\n

Contact presse : Oc\u00e9ane Chapin – ochapin@angiocom.fr – 07 78 56 73 55<\/p>\n","protected":false},"excerpt":{"rendered":"

Communiqu\u00e9 de presse \u2013 25 avril 2024 CP Curecall – avril 2024   Curecall, Bouygues Telecom et CM.com r\u00e9volutionnent le suivi m\u00e9dical des patients atteints d\u2019un glaucome gr\u00e2ce \u00e0 la solution Time2Chat   Curecall, pionnier du suivi m\u00e9dical \u00e0 distance des patients chroniques, CM.com et Bouygues Telecom s’associent pour mettre en place le suivi \u00e0 […]<\/p>\n","protected":false},"author":1,"featured_media":18326,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[19,21],"tags":[],"class_list":["post-26652","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites","category-informations"],"acf":[],"yoast_head":"\nTime2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome | Unither<\/title>\n<meta name=\"description\" content=\"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome | Unither\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome | Unither\" \/>\n<meta property=\"og:description\" content=\"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome | Unither\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/\" \/>\n<meta property=\"og:site_name\" content=\"Unither\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-19T08:55:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T13:33:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.unither-pharma.biz\/wp-content\/uploads\/2024\/04\/communique-cp-curecall.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1287\" \/>\n\t<meta property=\"og:image:height\" content=\"547\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@UnitherPharma\" \/>\n<meta name=\"twitter:site\" content=\"@UnitherPharma\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/#\/schema\/person\/eb53be7b5e854190989b3a8783d0cc28\"},\"headline\":\"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome\",\"datePublished\":\"2024-04-19T08:55:35+00:00\",\"dateModified\":\"2026-04-15T13:33:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/\"},\"wordCount\":538,\"publisher\":{\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.unither-pharma.biz\/wp-content\/uploads\/2024\/04\/communique-cp-curecall.png\",\"articleSection\":[\"Actualit\u00e9s\",\"Informations\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/\",\"url\":\"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/\",\"name\":\"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome | Unither\",\"isPartOf\":{\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.unither-pharma.biz\/wp-content\/uploads\/2024\/04\/communique-cp-curecall.png\",\"datePublished\":\"2024-04-19T08:55:35+00:00\",\"dateModified\":\"2026-04-15T13:33:00+00:00\",\"description\":\"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome | Unither\",\"breadcrumb\":{\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/#primaryimage\",\"url\":\"https:\/\/www.unither-pharma.biz\/wp-content\/uploads\/2024\/04\/communique-cp-curecall.png\",\"contentUrl\":\"https:\/\/www.unither-pharma.biz\/wp-content\/uploads\/2024\/04\/communique-cp-curecall.png\",\"width\":1287,\"height\":547},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.unither-pharma.biz\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/#website\",\"url\":\"https:\/\/www.unither-pharma.biz\/fr\/\",\"name\":\"Unither\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.unither-pharma.biz\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/#organization\",\"name\":\"Unither\",\"url\":\"https:\/\/www.unither-pharma.biz\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.unither-pharma.biz\/wp-content\/uploads\/2026\/01\/logo-unither-pharmaceuticals-site-internet.png\",\"contentUrl\":\"https:\/\/www.unither-pharma.biz\/wp-content\/uploads\/2026\/01\/logo-unither-pharmaceuticals-site-internet.png\",\"width\":514,\"height\":252,\"caption\":\"Unither\"},\"image\":{\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/UnitherPharma\",\"https:\/\/www.linkedin.com\/company\/unither-pharmaceuticals\/\",\"https:\/\/www.youtube.com\/channel\/UCHaTbYrnICFU1MiLwNsKjMA\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.unither-pharma.biz\/fr\/#\/schema\/person\/eb53be7b5e854190989b3a8783d0cc28\",\"name\":\"admin\",\"sameAs\":[\"https:\/\/www.unither-pharma.biz\"],\"url\":\"https:\/\/www.unither-pharma.biz\/fr\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome | Unither","description":"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome | Unither","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/","og_locale":"fr_FR","og_type":"article","og_title":"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome | Unither","og_description":"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome | Unither","og_url":"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/","og_site_name":"Unither","article_published_time":"2024-04-19T08:55:35+00:00","article_modified_time":"2026-04-15T13:33:00+00:00","og_image":[{"width":1287,"height":547,"url":"https:\/\/www.unither-pharma.biz\/wp-content\/uploads\/2024\/04\/communique-cp-curecall.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_creator":"@UnitherPharma","twitter_site":"@UnitherPharma","twitter_misc":{"\u00c9crit par":"admin","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/#article","isPartOf":{"@id":"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/"},"author":{"name":"admin","@id":"https:\/\/www.unither-pharma.biz\/fr\/#\/schema\/person\/eb53be7b5e854190989b3a8783d0cc28"},"headline":"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome","datePublished":"2024-04-19T08:55:35+00:00","dateModified":"2026-04-15T13:33:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/"},"wordCount":538,"publisher":{"@id":"https:\/\/www.unither-pharma.biz\/fr\/#organization"},"image":{"@id":"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.unither-pharma.biz\/wp-content\/uploads\/2024\/04\/communique-cp-curecall.png","articleSection":["Actualit\u00e9s","Informations"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/","url":"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/","name":"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome | Unither","isPartOf":{"@id":"https:\/\/www.unither-pharma.biz\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/#primaryimage"},"image":{"@id":"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.unither-pharma.biz\/wp-content\/uploads\/2024\/04\/communique-cp-curecall.png","datePublished":"2024-04-19T08:55:35+00:00","dateModified":"2026-04-15T13:33:00+00:00","description":"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome | Unither","breadcrumb":{"@id":"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/#primaryimage","url":"https:\/\/www.unither-pharma.biz\/wp-content\/uploads\/2024\/04\/communique-cp-curecall.png","contentUrl":"https:\/\/www.unither-pharma.biz\/wp-content\/uploads\/2024\/04\/communique-cp-curecall.png","width":1287,"height":547},{"@type":"BreadcrumbList","@id":"https:\/\/www.unither-pharma.biz\/fr\/time2chat-suivi-medical-des-patients-atteints-dun-glaucome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.unither-pharma.biz\/fr\/"},{"@type":"ListItem","position":2,"name":"Time2Chat : suivi m\u00e9dical des patients atteints d\u2019un glaucome"}]},{"@type":"WebSite","@id":"https:\/\/www.unither-pharma.biz\/fr\/#website","url":"https:\/\/www.unither-pharma.biz\/fr\/","name":"Unither","description":"","publisher":{"@id":"https:\/\/www.unither-pharma.biz\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.unither-pharma.biz\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.unither-pharma.biz\/fr\/#organization","name":"Unither","url":"https:\/\/www.unither-pharma.biz\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.unither-pharma.biz\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.unither-pharma.biz\/wp-content\/uploads\/2026\/01\/logo-unither-pharmaceuticals-site-internet.png","contentUrl":"https:\/\/www.unither-pharma.biz\/wp-content\/uploads\/2026\/01\/logo-unither-pharmaceuticals-site-internet.png","width":514,"height":252,"caption":"Unither"},"image":{"@id":"https:\/\/www.unither-pharma.biz\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/UnitherPharma","https:\/\/www.linkedin.com\/company\/unither-pharmaceuticals\/","https:\/\/www.youtube.com\/channel\/UCHaTbYrnICFU1MiLwNsKjMA"]},{"@type":"Person","@id":"https:\/\/www.unither-pharma.biz\/fr\/#\/schema\/person\/eb53be7b5e854190989b3a8783d0cc28","name":"admin","sameAs":["https:\/\/www.unither-pharma.biz"],"url":"https:\/\/www.unither-pharma.biz\/fr\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.unither-pharma.biz\/fr\/wp-json\/wp\/v2\/posts\/26652","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unither-pharma.biz\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unither-pharma.biz\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unither-pharma.biz\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unither-pharma.biz\/fr\/wp-json\/wp\/v2\/comments?post=26652"}],"version-history":[{"count":2,"href":"https:\/\/www.unither-pharma.biz\/fr\/wp-json\/wp\/v2\/posts\/26652\/revisions"}],"predecessor-version":[{"id":26935,"href":"https:\/\/www.unither-pharma.biz\/fr\/wp-json\/wp\/v2\/posts\/26652\/revisions\/26935"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.unither-pharma.biz\/fr\/wp-json\/wp\/v2\/media\/18326"}],"wp:attachment":[{"href":"https:\/\/www.unither-pharma.biz\/fr\/wp-json\/wp\/v2\/media?parent=26652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unither-pharma.biz\/fr\/wp-json\/wp\/v2\/categories?post=26652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unither-pharma.biz\/fr\/wp-json\/wp\/v2\/tags?post=26652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}